Depression
SSRIs, SNRIs and an atypical. Off-patent and multi-sourced, but the most under-treated field — demand sits behind a diagnosis gap, not a supply gap.
480,000
Estimated patients
Burden: NHMS 2023 (2023) · * Coarse open estimate — NHMS 2019 treated patients × MOH published therapy cost (~1 DDD/day). Order-of-magnitude; precise molecule-level size & market concentration are in the read.
Market structure, at a glance.
The 8 tracked molecules in this field, grouped by makers and patent status. A neutral count — no verdict.
6 generic-open
2 multi-source
Generic-open — off-patent, generics registeredMulti-source — 10+ registered makers